Background: The Asian population with atrial fibrillation (AF) have a higher risk of stroke
than the caucasian population and a higher risk of intracranial bleeding when …

Background Little is known about the comparative effectiveness and safety of non–vitamin K
antagonist oral anticoagulants (NOAC) compared to warfarin in Chinese atrial fibrillation …

Objective: This analysis was performed to evaluate the efficacy in stroke prevention and
safety of dabigatran in Chinese nonvalvular atrial fibrillation (NVAF) patients enrolled in RE …

Background: Dabigatran is an oral direct thrombin inhibitor recently approved for stroke
prevention in atrial fibrillation (AF) as an alternative to warfarin. The primary advantages of …

BACKGROUND Most of the randomized clinical trials that led to the wide use of non-vitamin
K antagonist oral anticoagulants for stroke prevention in patients with atrial fibrillation (AF) …

Background: Although non-vitamin K antagonist oral anticoagulants (NOACs) are approved
for stroke prevention in atrial fibrillation (AF) patients, their use in the local clinical setting has …

Background and Purpose—Whether dabigatran is associated with different risks of
cardiovascular, bleeding events, and mortality from warfarin in Asian patients with …

Background Little is known about the clinical benefit of a non–vitamin K antagonist oral
anticoagulant compared with warfarin in elderly Chinese patients with atrial fibrillation (AF) …

Introduction: Atrial fibrillation (AF) is the most common cardiac arrhythmia with significant
morbidity and mortality in relation to thromboembolic stroke. Our study aimed to evaluate the …

Background and purpose GLORIA-AF is a large, global, prospective registry program of
newly diagnosed atrial fibrillation (AF) patients with≥ 1 stroke risk factors. We describe the …